Loading…
ORIC Pharmaceuticals, Inc. is projected to rise to $9.89 by 2027, a +15% move from its current price of $8.58. ORIC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.33 | $8.58 | $8.84 | +0.04% |
| May 30 | $8.23 | $8.59 | $8.96 | +0.08% |
| May 31 | $8.16 | $8.59 | $9.05 | +0.12% |
| Jun 1 | $8.10 | $8.59 | $9.12 | +0.16% |
| Jun 2 | $8.04 | $8.60 | $9.19 | +0.20% |
| Jun 3 | $8.00 | $8.60 | $9.25 | +0.24% |
| Jun 4 | $7.95 | $8.60 | $9.31 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.95 | $8.60 | $9.31 | +0.28% |
| Week 2 | $7.72 | $8.63 | $9.65 | +0.57% |
| Week 3 | $7.55 | $8.65 | $9.92 | +0.85% |
| Week 4 | $7.41 | $8.68 | $10.16 | +1.14% |
| Week 5 | $7.30 | $8.70 | $10.38 | +1.42% |
| Week 6 | $7.19 | $8.73 | $10.58 | +1.71% |
| Week 7 | $7.10 | $8.75 | $10.78 | +1.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its focus includes two clinical-stage product candidates: enozertinib, formerly ORIC-114, described as a brain penetrant orally bioavailable irreversible inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency toward exon 20 insertion mutations; and rinzimetostat, formerly ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
The company has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor, and a collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc. (ORIC) operates in the Healthcare space as a clinical-stage biopharmaceutical company focused on cancer resistance mechanisms. The current price is $8.32 and the market cap is $861.27M. Its rank is 2640.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 26.9% above — a clean break opens room to run.
A major ceiling 61.8% above — clearing it would confirm fresh momentum.
Key ORIC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORIC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.46 | Buy | $8.46 | Buy |
| MA 10 | $8.33 | Buy | $8.51 | Buy |
| MA 20 | $8.82 | Sell | $8.84 | Sell |
| MA 50 | $9.87 | Sell | $9.65 | Sell |
| MA 100 | $10.58 | Sell | $10.19 | Sell |
| MA 200 | $10.84 | Sell | $10.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.98 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -32.49 | Neutral |
| Williams %R (14) | -38.68 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -3.05 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 61.32 | Neutral |
| TRIX (15) | -0.80 | Sell |
| Awesome (5,34) | -1.01 | Sell |
| Ultimate (7,14,28) | 54.87 | Neutral |
| Momentum (10) | -0.25 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 8.57 | Buy |
| ADX (14) | 21.89 | Sell |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is neutral overall. The RSI14 sits at 40, with the 50-day simple moving average (SMA50) at $10.01 and the 200-day simple moving average (SMA200) at $10.85. Near-term support is indicated at $7.93 and resistance at $10.89, framing a 30-day range from $6.77 to $10.22.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.47 | $8.58 | $11.04 | 0% | Neutral | |
| $7.77 | $9.89 | $13.36 | +15% | Neutral | |
| $7.76 | $10.16 | $14.28 | +18% | Neutral | |
| $8.88 | $11.93 | $17.27 | +39% | Bullish | |
| $11.27 | $15.49 | $23.01 | +81% | Bullish | |
| $12.34 | $17.31 | $26.30 | +102% | Bullish | |
| $12.67 | $18.11 | $28.07 | +111% | Bullish | |
| $12.44 | $18.11 | $28.58 | +111% | Bullish | |
| $13.40 | $19.85 | $31.85 | +131% | Bullish | |
| $15.48 | $23.30 | $37.99 | +172% | Bullish | |
| $20.81 | $33.77 | $58.75 | +294% | Bullish | |
| $37.96 | $70.20 | $134.28 | +718% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.47 | $8.58 | $10.08 | +0.00% |
| June 2026 | $7.43 | $8.75 | $10.55 | +1.93% |
| July 2026 | $7.50 | $8.90 | $10.89 | +1.78% |
| August 2026 | $7.23 | $8.65 | $10.70 | -2.86% |
| September 2026 | $7.07 | $8.51 | $10.62 | -1.63% |
| October 2026 | $7.23 | $8.75 | $11.02 | +2.90% |
| November 2026 | $7.25 | $8.82 | $11.19 | +0.75% |
| December 2026 | $7.07 | $8.64 | $11.04 | -2.01% |
Click any year to see its month-by-month ORIC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ORIC Pharmaceuticals, Inc.'s 2026 outlook centres on $8.58, within a $7.47 to $11.04 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ORIC could reach as high as $13.36, with a base case around $9.89 and support toward $7.77 — roughly +15% from $8.58. A consolidation phase looks the most probable path here.
Expect ORIC to range from $7.76 to $14.28 through 2028. The $10.16 average target implies a +18% move from current prices. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
The ORIC price prediction for 2029 points to an average of $11.93 (low $8.88, high $17.27) — a potential gain of +39% on today's $8.58. Buyers look set to stay in control over this stretch.
In 2030, ORIC is projected to trade between $11.27 and $23.01, averaging $15.49 — a potential gain of +81% from today's $8.58. That is up +30% on the projected 2029 average. Momentum favours further upside here.
ORIC Pharmaceuticals, Inc.'s 2031 outlook centres on $17.31, within a $12.34 to $26.30 range. That is up +12% on the projected 2030 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ORIC could reach as high as $28.07, with a base case around $18.11 and support toward $12.67 — roughly +111% from $8.58. Momentum favours further upside here.
Expect ORIC to range from $12.44 to $28.58 through 2033. The $18.11 average target implies a +111% move from current prices. That is up 0% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ORIC price prediction for 2034 points to an average of $19.85 (low $13.40, high $31.85) — a potential gain of +131% on today's $8.58. Momentum favours further upside here.
In 2035, ORIC is projected to trade between $15.48 and $37.99, averaging $23.30 — a potential gain of +172% from today's $8.58. That is up +17% on the projected 2034 average. Buyers look set to stay in control over this stretch.
ORIC Pharmaceuticals, Inc.'s 2040 outlook centres on $33.77, within a $20.81 to $58.75 range. That is up +45% on the projected 2035 average. That marks a +294% change versus current levels. Momentum favours further upside here.
By 2050, ORIC could reach as high as $134.28, with a base case around $70.20 and support toward $37.96 — roughly +718% from $8.58. Buyers look set to stay in control over this stretch.
Investing $1,000 in ORIC today (≈ 116.550117 ORIC) could be worth
$8,182.19
+$7,182.19 (+718%) by 2050 · US Dollar
Based on the average projected ORIC price of $70.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORICwould be worth at today's price.
$1,000 invested in ORIC on May 27, 2025 (≈ 173.010374 ORIC) would be worth
$1,484.43
+$484.43 (+48.4%) today · 1.48× · US Dollar
Based on a ORIC entry price of $5.78 vs. today's $8.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.41 | $1,020.21 | +2.0% |
| 1 month ago | $10.19 | $842 | -15.8% |
| 3 months ago | $13.5 | $635.56 | -36.4% |
| 6 months ago | $11.88 | $722.22 | -27.8% |
| 1 year ago | $5.78 | $1,484.43 | +48.4% |
| All time (5.0y) ago | $23.04 | $372.4 | -62.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORIC forecast.
Our base-case forecast reaches $17.00 around 2031.
Implied market cap at $17.00: $1.76B
Forecasts show a progressively bullish long-term trajectory with rising average prices and sizable ROIs across the years. The 2026 min, avg, max are $7.47, $8.32, $10.82 with ROI 0 and sentiment NEUTRAL. In 2027, the min, avg, max are $7.72, $9.87, $13.44 with ROI 18.7 and sentiment NEUTRAL.
The 2028 forecast is min $7.69, avg $10.16, max $14.39 with ROI 22.1 and sentiment BULLISH, followed by 2029 min $9.05, avg $12.26, max $17.93 with ROI 47.4 and sentiment BULLISH. By 2030 the model projects min $11.76, avg $16.32, max $24.50 with ROI 96.1 and sentiment BULLISH, rising further through 2031(min $12.74, avg $18.07, max $27.77, ROI 117.2), 2032(min $13.13, avg $19.00, max $29.81, ROI 128.4), 2033(min $13.09, avg $19.30, max $30.86, ROI 132), 2034(min $14.09, avg $21.15, max $34.40, ROI 154.2), and 2035(min $16.63, avg $25.41, max $41.99, ROI 205.4). The long-term horizon extends to 2040 (min $22.42, avg $37.11, max $65.59, ROI 346, sentiment BULLISH) and 2050 (min $41.64, avg $79.32, max $154.56, ROI 853.3, sentiment BULLISH).
These figures point to a strong upside potential over the extended horizon, albeit with inherent uncertainty and the usual investment risks.
Tap a question to reveal the answer.
The 2026 forecast shows min $7.47, avg $8.32, max $10.82 with ROI 0 and sentiment NEUTRAL.
The 2027 forecast shows min $7.72, avg $9.87, max $13.44 with ROI 18.7 and sentiment NEUTRAL.
The 2030 forecast shows min $11.76, avg $16.32, max $24.50 with ROI 96.1 and sentiment BULLISH.
The 2050 forecast shows min $41.64, avg $79.32, max $154.56 with ROI 853.3 and sentiment BULLISH.
The current price is $8.32 and the market cap is $861.27M.
ORIC Pharmaceuticals, Inc. Community Discussion
0Share your ORIC Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.